Journey Medical Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $17.6 million, a 21% increase from $14.6 million in the same period last year. The growth was primarily driven by a 16% rise in product revenue, which reached $17.0 million, bolstered by the commercial launch of its new product, Emrosi™, which contributed $4.9 million in revenue. The company also recognized $606,000 in other revenue from the supply of Amzeeq to Cutia, marking a significant milestone in its product portfolio.
In terms of profitability, Journey Medical recorded a net loss of $2.3 million for the quarter, a slight improvement from a loss of $2.4 million in the prior year. The loss from operations decreased by 47% to $1.5 million, attributed to a reduction in operating expenses, which rose only 9% to $19.2 million compared to the previous year. Notably, research and development expenses fell significantly by 66% to $287,000, reflecting a decrease in pre-approval project costs associated with Emrosi. Selling, general, and administrative expenses increased by 6% to $12.1 million, driven by activities related to the product launch.
The company’s balance sheet showed an increase in total assets to $85.2 million as of September 30, 2025, up from $80.2 million at the end of 2024. Cash and cash equivalents rose to $24.9 million, compared to $20.3 million at the end of the previous fiscal year. Journey Medical's working capital also improved to $16.7 million, up from $13.0 million, indicating a stronger liquidity position. The company’s total liabilities decreased slightly to $59.3 million, down from $60.2 million, reflecting effective management of its debt obligations.
Strategically, Journey Medical has made significant moves to enhance its operational capabilities. In August 2025, the company entered into a new At Market Issuance Sales Agreement, allowing it to sell up to 3.75 million shares of common stock to raise additional capital. Furthermore, on September 25, 2025, the company amended its Credit Agreement with SWK Funding LLC, extending the maturity date of its credit facility and lowering the revenue threshold for interest-only payments, which could provide more financial flexibility moving forward.
Looking ahead, Journey Medical remains focused on expanding its product offerings and market presence. The company is actively evaluating opportunities for additional product acquisitions and partnerships to enhance its portfolio. However, it also acknowledges the challenges posed by market competition and regulatory pressures, which could impact future revenue growth. The management expressed cautious optimism about the upcoming quarters, particularly with the anticipated performance of Emrosi and other products in its pipeline.
About Journey Medical Corp
Journey Medical Corporation is a pharmaceutical company specializing in the development, marketing, and sale of FDA-approved dermatology products. Its portfolio includes treatments for rosacea, acne, hyperhidrosis, fungal infections, and skin conditions, primarily sold through specialty pharmacies and distributors in the U.S. The company leverages licensing, acquisitions, and proprietary technologies to innovate and expand its product offerings in the dermatology market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.